Core Insights - IO Biotech announced the publication of long-term clinical and immunological outcomes from the MM1636 trial, which evaluated the investigational peptide vaccine IO102-IO103 in combination with PD-1 blockade for treating first-line metastatic melanoma [1][2] Group 1: Clinical Trial Results - The five-year follow-up analysis of the MM1636 trial showed a median progression-free survival (PFS) of 25.5 months, indicating durable clinical activity [2][7] - The trial identified potential vaccine-specific immune biomarkers associated with long-term benefits, which were not observed in a matched anti-PD-1 monotherapy cohort, suggesting enhanced anti-tumor activity through vaccine-induced immune modulation [2][7] - The median duration of response exceeded 53 months, and the median overall survival reached 60 months, supporting the potential of IO102-IO103 as a first-line therapy for melanoma [3] Group 2: Company Strategy and Future Trials - IO Biotech is advancing its lead cancer vaccine candidate, Cylembio (IO102-IO103), in clinical trials, with plans to initiate a Phase 3 clinical trial (IOB-013/KN-D18) for first-line advanced melanoma [1][9] - The IOB-013/KN-D18 trial has enrolled 407 patients across multiple countries, with primary endpoints focused on progression-free survival and secondary endpoints including overall response rate and safety assessments [9] - The company emphasizes the significant unmet need for innovative therapies in cancer treatment, reinforcing its commitment to developing off-the-shelf immune-modulatory therapeutics with potential applications across various cancers [4]